Robert Brenner - 18 Feb 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Medical Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
18 Feb 2025
Net transactions value
$0
Form type
4
Filing time
20 Feb 2025, 16:10:21 UTC
Previous filing
08 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Award $0 +26,900 +4686% $0.000000 27,474 18 Feb 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Award $0 +53,800 $0.000000 53,800 18 Feb 2025 Class A Common Stock 53,800 $29.18 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
F2 Includes 574 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 13, 2024.
F3 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.